Michael Mingzhao Xing, M.D., Ph.D., is the Founding Dean of School of Medicine and Chair Professor, Southern University of Science and Technology (SUSTech) in Shenzhen, Guangdong, China and Professor of Medicine (LOA), the Johns Hopkins University School of Medicine in Baltimore, Maryland, USA. Before joining SUSTech, he had been tenured Professor of Medicine at the Johns Hopkins University School of Medicine. He was also Professor of Oncology, Pathology, and Cellular & Molecular Medicine, Director of the Johns Hopkins Clinical Thyroid Tumor Center, and Chief of the Laboratory for Cellular and Molecular Thyroid Research at the Johns Hopkins University School of Medicine.
Dr Xing graduated in 1984 from the Medicine Branch of the Second Military Medical University in Shanghai, China and received a Ph.D. in 1993 in Physiology and Biophysics from Case Western Reserve University in Cleveland, Ohio, USA. He completed a four-year Postdoctoral Research Fellowship in 1997 at National Institutes of Health (NIH) and the University of California, San Diego, a three-year Residency in Internal Medicine in 2000 at Greater Baltimore Medical Center (honored with the Best Resident Award at graduation), and a three-year Clinical Fellowship in Endocrinology, Diabetes & Metabolism in 2003 at the Johns Hopkins Hospital in Baltimore, Maryland, USA. For his outstanding performance on the endocrine fellowship program, upon graduation he was recruited to the Faculty of Johns Hopkins Department of Medicine as Assistant Professor of Medicine in 2003. He subsequently rose to Associate Professor in 2006 and tenured Full Professor in 2011 at the Johns Hopkins School of Medicine. American board-certified dually in Internal Medicine and Endocrinology & Metabolism, Dr. Xing had been working for nearly two decades at Johns Hopkins Hospital as an internist/endocrine subspecialty consultant and teaching attending while directing the Cellular and Molecular Thyroid Research Laboratory as a physician scientist at the Johns Hopkins School of Medicine.
Dr. Xing’s main clinical and research interests are in thyroid diseases, particularly thyroid dysfunctions and thyroid tumor. As a continuously well-funded Principal Investigator, his research has focused on studying molecular mechanisms and genetic basis of thyroid tumor and their clinical translation. He has 180 publications in various prestigious journals, such as JCEM, Clinical Cancer Research, Cancer Research, Journal of Clinical Investigation, Journal of National Cancer Institute, Journal of Clinical Oncology, Nature Communications, JAMA Oncology, Lancet, JAMA, Nature Reviews Cancer, Endocrine Reviews, and PNAS . He holds/co-holds ten USA patents on such seminal thyroid research contributions as initial discovery and clinical characterization of the BRAF V600E and TERT promoter mutations in thyroid cancer and initial demonstration of targeting BRAF/MEK to restore thyroid gene expression and radioiodine uptake for radioiodine treatment of thyroid cancer. His work has been heavily referenced in the clinical guidelines for the management of thyroid tumors of authoritative organizations, such as the American Thyroid Association, and has had a profound impact on today's molecular-based precision management of thyroid tumor. Dr. Xing’s work is consistently among world's top 0.01% citations in the thyroid field, with a total of >20,000 citations and accumulated IF of 1,350.
As a world-renowned physician scientist and clinical thyroid specialist, Dr. Xing has been recognized with numerous leadership roles on prestigious international professional programs/committees, such as the standing membership on the NIH’s Molecular and Cellular Endocrinology study (grant) committee, the American Thyroid Association’s Organizing Committee Co-Chair and Research Committee Chair, Consulting Editor of Journal of Clinical Investigation, Associate Editor of the ATA’s journal Thyroid. He has accepted and completed >200 invited talks at prestigious universities and international scientific and medical conferences. Dr. Xing has also been recognized with numerous prestigious awards, among which are the 2006 Maryland Innovator Award, the 2013 British Endocrine Society's Endocrine-Related Cancer Research Award, the 2014 Chinese Endocrine Society's Zhu Xianyi Award, the 2016 American Thyroid Association's Paul Starr Award, and the Johns Hopkins' 2017 Paul W Ladenson Thyroid Award. Dr. Xing has been consistently recognized among the "World's Top Ten Thyroid Tumor Scholar Experts" by the USA Expertscape （http://www.prlog.org/12257413.html；https://expertscape.com/ex/thyroid+cancer%2C+papillary ) and "America's Top Doctors" by authoritative professional recognition entities. He was elected and induced into the membership of the prestigious Association of American Physicians in 2019.